Evidence map›Paper›PMID 39699942›Full record

ArticleeLife2024

N-terminus of

Valentin Babosha, Natalia Klimenko, Anastasia Revel-Muroz, Evgeniya Tikhonova, Pavel Georgiev, Oksana Maksimenko

Abstract read
In one paragraph

Article in eLife, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. N-terminus ofeLife · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Valentin BaboshaDepartment of the Control of Genetic Processes, Institute of Gene Biology, Russian Academy of Sciences, Moscow, Russian Federation.
Natalia KlimenkoCenter for Precision Genome Editing and Genetic Technologies for Biomedicine, Institute of Gene Biology, Russian Academy of Sciences, Moscow, Russian Federation.
Anastasia Revel-MurozCenter for Precision Genome Editing and Genetic Technologies for Biomedicine, Institute of Gene Biology, Russian Academy of Sciences, Moscow, Russian Federation.
Evgeniya TikhonovaDepartment of the Control of Genetic Processes, Institute of Gene Biology, Russian Academy of Sciences, Moscow, Russian Federation.
Pavel GeorgievDepartment of the Control of Genetic Processes, Institute of Gene Biology, Russian Academy of Sciences, Moscow, Russian Federation.
Oksana MaksimenkoCenter for Precision Genome Editing and Genetic Technologies for Biomedicine, Institute of Gene Biology, Russian Academy of Sciences, Moscow, Russian Federation.ORCID https://orcid.org/0000-0003-3502-0303

Funding

Ministry of Science and Higher Education of the Russian Federation 075-15-2019-1661Russian Science Foundation 21-14-00211
6 · The paper itself

Abstract

The male-specific lethal complex (MSL), which consists of five proteins and two non-coding roX RNAs, is involved in the transcriptional enhancement of X-linked genes to compensate for the sex chromosome monosomy in

Indexed as

Dosage Compensation, GeneticDrosophila melanogasterDrosophila ProteinsX ChromosomeAnimalsDNA-Binding ProteinsFemaleMaleNuclear ProteinsProtein BindingTranscription FactorsDNA-Binding ProteinsDrosophila Proteinsmsl-1 protein, DrosophilaNuclear ProteinsTranscription Factorschromosomesdevelopmental biologyD. melanogastergene expressionMSL2MSL3MSL complexRNA-protein interactionsex determinationtranscription factor

Identifiers

PMID39699942
PMCPMC11658772

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.